-
-
-
-
-
-
-
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
-
-
-
-
-
-
-
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum
-
-
-
-
-
-
-
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
-
1,167,056 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

